| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
13,030,000 |
| Market
Cap: |
52.12(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.34 - $22.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 634 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Eagle Pharmaceuticals is a pharmaceutical company focused on developing medicines to treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. Co.'s products include: Belrapzo® (bendamustine ready-to-dilute (RTD) 500ml solution), Bendeka® (infused bendamustine RTD) and Treakisym® for chronic lymphocytic leukemia and non-hodgkin's lymphoma; Ryanodex® (dantrolene sodium) for malignant hyperthermia; EP-4104 Ryanodex® (dantrolene sodium) for the treatment of organophosphate exposure; PEMFEXY™ (pemetrexed for injection) for lung cancer; and EA-114 (fulvestrant) for breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
20,245 |
87,045 |
| Total Sell Value |
$0 |
$0 |
$300,027 |
$1,741,115 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
2 |
7 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Krill Steven L. |
EVP & Chief Scientific Officer |
• – – |
2016-12-13 |
4 |
OE |
$4.42 |
$44,200 |
D/D |
10,000 |
10,000 |
|
- |
|
| Ratoff Steven B |
Director |
– • – |
2016-12-13 |
4 |
S |
$75.00 |
$652,500 |
D/D |
(8,700) |
13,324 |
|
- |
|
| Ratoff Steven B |
Director |
– • – |
2016-12-12 |
4 |
S |
$75.07 |
$97,591 |
D/D |
(1,300) |
22,024 |
|
- |
|
| Krill Steven L. |
EVP & Chief Scientific Officer |
• – – |
2016-11-30 |
4 |
S |
$80.00 |
$462,960 |
D/D |
(5,787) |
0 |
|
- |
|
| Krill Steven L. |
EVP & Chief Scientific Officer |
• – – |
2016-11-30 |
4 |
OE |
$4.42 |
$45,111 |
D/D |
5,787 |
1,307 |
|
- |
|
| Flaum Sander A |
Director |
– • – |
2016-11-28 |
4 |
S |
$78.66 |
$393,300 |
D/D |
(5,000) |
11,374 |
|
- |
|
| Krill Steven L. |
EVP & Chief Scientific Officer |
• – – |
2016-11-23 |
4 |
S |
$80.00 |
$16,000 |
D/D |
(200) |
0 |
|
- |
|
| Krill Steven L. |
EVP & Chief Scientific Officer |
• – – |
2016-11-23 |
4 |
OE |
$8.78 |
$1,756 |
D/D |
200 |
200 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-11-11 |
4 |
S |
$85.00 |
$1,321,835 |
I/I |
(15,551) |
3,944,401 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-11-10 |
4 |
S |
$85.00 |
$1,614,770 |
I/I |
(18,935) |
26,174 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-11-09 |
4 |
S |
$75.70 |
$11,818,065 |
I/I |
(148,800) |
3,977,287 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-11-07 |
4 |
S |
$75.39 |
$379,212 |
I/I |
(5,030) |
4,126,087 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-11-04 |
4 |
S |
$75.00 |
$3,462,750 |
I/I |
(46,170) |
4,181,446 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-11-02 |
4 |
S |
$70.00 |
$13,992,635 |
I/I |
(199,600) |
27,474 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-09-30 |
4 |
S |
$70.06 |
$1,548,326 |
I/I |
(22,100) |
4,373,987 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-09-21 |
4 |
S |
$66.15 |
$6,603,416 |
I/I |
(99,795) |
29,574 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-09-08 |
4 |
S |
$62.33 |
$2,124,580 |
I/I |
(34,086) |
30,228 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-09-07 |
4 |
S |
$62.26 |
$712,379 |
I/I |
(11,442) |
30,452 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-09-06 |
4 |
S |
$62.45 |
$1,595,904 |
I/I |
(25,397) |
30,527 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-08-24 |
4 |
S |
$62.78 |
$728,562 |
I/I |
(11,605) |
30,693 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-08-23 |
4 |
S |
$63.12 |
$1,090,109 |
I/I |
(17,265) |
30,769 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-08-17 |
4 |
S |
$60.85 |
$897,619 |
I/I |
(14,696) |
30,882 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-08-16 |
4 |
S |
$60.66 |
$3,709,391 |
I/I |
(60,150) |
30,978 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2016-08-15 |
4 |
S |
$60.51 |
$1,516,160 |
I/I |
(24,949) |
31,372 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2016-07-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
950,600 |
|
- |
|
222 Records found
|
|
Page 7 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.46 (12.99%) 
